Pregabalin in the treatment of alcohol and benzodiazepines dependence

CNS Neuroscience and Therapeutics

Volumn 16, Issue 1, 2010, Pages 45-50

  Oulis, Panagiotis ^a   Konstantakopoulos, George ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Alcohol dependence; Benzodiazepines dependence; Clinical trials; Pregabalin; Withdrawal syndrome

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DIAZEPAM; NALTREXONE; PREGABALIN;

ALCOHOLISM; ANXIETY DISORDER; CLINICAL TRIAL; COMORBIDITY; CONVULSION; DISEASE SEVERITY; DIZZINESS; DRUG DEPENDENCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSARTHRIA; ELECTROENCEPHALOGRAM; FATIGUE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; LEG CRAMP; MINI MENTAL STATE EXAMINATION; MOOD DISORDER; OPEN STUDY; QUALITY OF LIFE; REBOUND; RELAPSE; REVIEW; SEDATION; SIDE EFFECT; SURVIVAL; WITHDRAWAL SYNDROME;

ALCOHOLISM; ANTICONVULSANTS; BENZODIAZEPINES; GAMMA-AMINOBUTYRIC ACID; HUMANS; SUBSTANCE-RELATED DISORDERS;

EID: 74549118824     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2009.00120.x     Document Type: Review

References (39)

1. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004 45 (Suppl 6 13 8.
2. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: A summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 2004 61 : 1 48.
3. Stahl SM. Mechanism of action of alpha2delta ligands: Voltage sensitive calcium channel (VSCC) modulators. J Clin Psychiatry 2004 65 : 1033 1034.
4. Kavoussi R. Pregabalin: From molecule to medicine. Eur Neuropsychopharmacol 2006 16 (Suppl 2 S128 S133.
5. Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel alpha2delta ligands: Novel modulators of neurotransmission. Trends Pharmacol Sci 2007 28 : 75 82.
6. Sills GJ. The mechanism of action of gabapentin and pregabalin. Curr Opin Pharmacol 2006 6 : 108 113.
7. Lauria-Horner BA, Pohl RB. Pregabalin: A new anxiolytic. Expert Opin Investig Drugs 2003 12 : 663 672.
8. Shneker BF, McAuley JW. Pregabalin: A new neuromodulator with broad therapeutic indications. Ann Pharmacother 2005 39 : 2029 2037.
9. Beydoun A, Nasreddine W, Atweh S. Efficacy and tolerability of pregabalin in partial epilepsy. Expert Rev Neurother 2008 8 : 1013 1024.
10. Lozsadi D, Hemming K, Marson AG. Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2008 1 : CD005612.
11. Sonnett TE, Setter SM, Campbell RK. Pregabalin for the treatment of painful neuropathy. Expert Rev Neurother 2006 6 : 1629 1635.
12. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009 3 : CD007076.
13. Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: A novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 2007 29 : 26 48.
14. Lyseng-Williamson KA, Siddiqui MA. Pregabalin: A review of its use in fibromyalgia. Drugs 2008 68 : 2205 2223.
15. Montgomery SA. Pregabalin for the treatment of generalised anxiety disorder. Expert Opin Pharmacother 2006 7 : 2139 2154.
16. Frampton JE, Foster RH. Pregabalin: In the treatment of generalised anxiety disorder. CNS Drugs 2006 20 : 685 693.
17. Owen RT. Pregabalin: Its efficacy, safety and tolerability profile in generalized anxiety. Drugs Today (Barc) 2007 43 : 601 610.
18. Bandelow B, Wedekind D, Leon T. Pregabalin for the treatment of generalized anxiety disorder: A novel pharmacologic intervention. Expert Rev Neurother 2007 7 : 769 781. (Pubitemid 47037717)
19. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ. WFSBP task force on treatment guidelines for anxiety, obsessive-compulsive and post-traumatic stress disorders. World J Biol Psychiatry 2008 9 : 248 312.
20. Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: A placebo-controlled, multicenter study. J Clin Psychopharmacol 2004 24 : 141 149.
21. Westenberg HG. Recent advances in understanding and treating social anxiety disorder. CNS Spectr 2009 14 (Suppl 3 24 33.
22. Zohar J, Matar MA, Ifergane G, Kaplan Z, Cohen H. Brief post-stressor treatment with pregabalin in an animal model for PTSD: Short-term anxiolytic effects without long-term anxiogenic effect. Eur Neuropsychopharmacol 2008 18 : 653 666.
23. Pae CU, Marks DM, Han C, Masand PS, Patkar AA. Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: An open label pilot study. Int Clin Psychopharmacol 2009 24 : 29 33.
24. Pae CU. Pregabalin augmentation to antidepressants in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009 33 : 577 578.
25. Showraki M. Pregabalin in the treatment of depression. J Psychopharmacol 2007 21 : 883 884.
26. Oulis P, Masdrakis VG, Karakatsanis NA, Karapoulios E, Kouzoupis AV, Konstantakopoulos G, Soldatos CR. Pregabalin in the discontinuation of long-term benzodiazepine use: A case-series. Int Clin Psychopharmacol 2008 23 : 110 112. (Pubitemid 351317284)
27. Oulis P, Konstantakopoulos G, Kouzoupis AV, et al. Pregabalin in the discontinuation of long-term benzodiazepines' use. Hum Psychopharmacol 2008 23 : 337 340. (Pubitemid 351982672)
28. Stein DJ, Baldwin DS, Baldinetti F, Mandel F. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: A pooled analysis of 6 studies. Eur Neuropsychopharmacol 2008 18 : 422 430.
29. Becker HC, Myrick H, Veatch LM. Pregabalin is effective against behavioral and electrographic seizures during alcohol withdrawal. Alcohol Alcohol 2006 41 : 399 406.
30. Martinotti G, Di Nicola M, Tedeschi D, Mazza M, Janiri L, Bria P. Efficacy and safety of pregabalin in alcohol dependence. Adv Ther 2008 25 : 608 618.
31. Martinotti G, Di Nicola M, Tedeschi D, et al. Pregabalin versus naltrexone in alcohol dependence: A randomised, double-blind, comparison trial. J Psychopharmacol 2009 doi :. [Epub ahead to print.]
32. Biermann T, Bleich S, Kornhuber J, Hillemacher T. Pregabalin in benzodiazepine withdrawal. Pharmacopsychiatry 2007 40 : 292 293.
33. Hindmarch I, Trick L, Ridout F. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology (Berl) 2005 183 : 133 143. (Pubitemid 41609265)
34. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: A 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006 67 : 771 782.
35. Martinotti G, Di Nicola M, Reina D, et al. Alcohol protracted withdrawal syndrome: The role of anhedonia. Subst Use Misuse 2008 43 : 271 284.
36. Denis C, Fatséas M, Lavie E, Auriacombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev 2006 3 : CD005194.
37. Siok CJ, Taylor CP, Hajós M. Anxiolytic profile of pregabalin on elicited hippocampal theta oscillation. Neuropharmacology 2009 56 : 379 385.
38. Pregabalin: Product Monograph (Last revision March 3, 2009). Quebec : Pfizer Canada Inc., 2009.
39. Chalabianloo F, Schjøtt J. Pregabalin og misbruk-spotensial. Tidsskr Nor Laegeforen 2009 129 : 186 187.